Skip to main navigation
Skip to search
Skip to main content
Oregon Health & Science University Home
Help & FAQ
Home
Profiles
Research units
Core Facilities
Publications
Search by expertise, name or affiliation
Imatinib as a paradigm of targeted therapies
Brian J. Druker
Knight Cancer Institute
Research output
:
Contribution to journal
›
Article
›
peer-review
308
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Imatinib as a paradigm of targeted therapies'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine & Life Sciences
Imatinib Mesylate
100%
Protein-Tyrosine Kinases
40%
Platelet-Derived Growth Factor Receptors
29%
Clinical Trials
28%
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
23%
Neoplasms
21%
Patient Selection
19%
Phosphotransferases
17%
Therapeutics
14%